Navigation Links
NuVasive to Present at Cowen and Company 29th Annual Healthcare Conference
Date:3/11/2009

SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Patrick Williams, Vice President Finance is scheduled to present at the Cowen & Company 29th Annual Healthcare Conference at The Boston Marriott Copley Place in Boston, Massachusetts on Wednesday, March 18, 2009, at 8:00 a.m. ET.

A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, the presentation will remain available on NuVasive's website for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of biologics, cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines four categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; biologics; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visibility and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation. NuVasive's Biologic product portfolio includes FormaGraft(R), Osteocel(R) Plus, and the Progentix(R) products, all of which are intended to facilitate fusion and complement the core fixation products.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NuVasive to Present at Barclays Capital Global Healthcare Conference
2. NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results
3. NuVasive Announces Web Cast and Conference Call of Fourth Quarter 2008 Results
4. NuVasive to Present at Canaccord Adams Musculoskeletal Conference
5. NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference
6. NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results
7. NuVasive to Present at 27th Annual J.P. Morgan Healthcare Conference
8. NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference
9. NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek
10. NuVasive to Present at Goldman Sachs 29th Annual Global Healthcare Conference
11. NuVasive Acquires First Stem Cell Bone Graft Substitute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for ... Care Association of America (HCAOA). This agreement allows HCAOA members to receive special ... as discounts on Accreditation University (AU) educational resources that help prepare HCAOA members ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Horizon Blue Cross ... the company’s credit rating of “A” and its outlook as “stable.” At the same ... reserves, which have fallen in recent years, dip below “capital adequacy” thresholds required for ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... Replace tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent ... rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a program ... delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in ... and decide to donate. , “Women’s Hospital at Renaissance has been a collection ...
(Date:4/28/2017)... ... April 28, 2017 , ... Bill Howe started his sewer and drain ... After Tina Howe joined the team, the Bill Howe brand was born and they ... rates, and giving back to the San Diego community in which they worked, lived ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: